Craft

Xenon Pharmaceuticals

Stock Price

$41.8

2024-10-29

Market Capitalization

$3.2 B

2024-10-29

Revenue

$7.5 M

FY, 2025

Xenon Pharmaceuticals Summary

Company Summary

Overview
We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical companies. We have built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. We have an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development.
Type
Public
Status
Active
Founded
1996
HQ
Burnaby, CA | view all locations
Website
https://www.xenon-pharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

LocationsView all

1 location detected

  • Burnaby, British Columbia HQ

    Canada

    3650 Gilmore Way

Xenon Pharmaceuticals Financials

Summary Financials

Net income (Q1, 2026)
($102.3M)
Cash (Q1, 2026)
$545.9M
EBIT (Q1, 2026)
($112.3M)
Enterprise value
$2.6B

Footer menu